Jose Mesa

Partner

2023 - Current

Board Director

2025

deepull is a development-stage clinical diagnostics company focusing on direct from blood sepsis diagnostics.

Board Director

2025

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

Board Director

2024

Board Director

2023

Developing microRNA modulators for diseases with unmet medical needs (DM1)

Board Observer

2024

Revolutionary intracellular screening platform enables a new generation of first-in-class drugs.

Director

2024

At Advanthera, we combine innovation, experience, and precision to bring advanced biotechnological solutions to the next development phase, ensuring they become readily accessible for the care of patients and caregivers, always upholding the highest standards of quality. From GMP-compliant development and manufacturing to pioneering research in new therapies, we work to ensure every breakthrough makes a real impact on people’s lives.

Board Director

2020 - 2022

Developing personalized adjuvant treatment strategies for early-stage breast cancer.

Board Director

2020 - 2022

Discovery and development of therapeutic biologics targeting the lipid metabolism in order to treat advanced cancer.

Board Director

2020 - 2022

DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.